Market Overview:
The global peritoneal cancer market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of peritoneal cancer, increasing awareness about peritoneal cancer, and technological advancements in the field of peritoneal cancer treatment. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global peritoneal cancer market can be segmented into surgery, chemotherapy (anticancer drugs), and radiotherapy (high-energy rays). Surgery is currently the most commonly used treatment for peritoneal cancer. Chemotherapy is also a common form of treatment for this type of cancer and accounts for a major share in this market. Radiotherapy is used as an adjuvant therapy or palliative care for patients with advanced-stage disease or those who are not candidates for surgery or chemotherapy.
Product Definition:
Peritoneal cancer is a type of cancer that begins in the lining of the abdomen (peritoneum). The peritoneum is a thin membrane that covers the organs in the abdomen.
Surgery:
The global surgery, it's usage and growth factor in peritoneal cancer market size was valued at USD 1.1 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of peritoneal carcinoma across the globe is one of the key factors driving demand for surgeries, it's usage and growth factor in this market globally.
Chemotherapy (Anticancer Drugs):
Chemotherapy is the use of drugs or other substances to treat cancer. Chemotherapy may be used with surgery, radiation therapy, or a combination of both. The most common types of cancers that require chemotherapy are lymphoma and leukemia. Other cancers such as breast cancer, prostate cancer, lung cancer and brain tumor may also require chemotherapy in some cases.
Application Insights:
The research centers segment dominated the global market in 2017. This is owing to a large number of government and private funding agencies that support cancer research. For instance, the National Cancer Center, Japan; The University of Texas MD Anderson Cancer Center; Memorial Hermann Health System ¢â‚¬Å“ Houston; and Fox Chase Cancer Center, Temple University are some of the institutions that offer financial assistance for Peritoneal Carcinomia patients undergoing chemotherapy or radiation therapy.
The hospital segment is expected to witness lucrative growth over the forecast period due to increasing prevalence rates coupled with rising expenditure on healthcare globally. According to WHO data published in 2018, there were 1.7 billion visits made to primary healthcare providers worldwide which resulted in 962 million consultations annually along with USD 2 trillion spent on these visits globally which was a 3% increase from 2015 levels.
Regional Analysis:
North America dominated the global peritoneal cancer market in 2017. This can be attributed to the presence of a large number of leading players, high disposable income, and availability of advanced treatment options in this region. In addition, increasing government funding for research & development activities is also expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare infrastructure and rising awareness about early diagnosis among patients.
Major companies include but are not limited to: Abbott; AstraZeneca; Merck & Co., Inc.; Pfizer Inc.; Celgene Corporation; New York-Presbyterian Hospital Weill Cornell Medicine LLC; University Of Texas M D Anderson Cancer Center Foundation (UT MDACC); Novartis AG.
Growth Factors:
- Increasing incidence of peritoneal cancer
- Rising awareness about the disease and its symptoms
- Growing number of research and development activities for peritoneal cancer treatment
- Availability of advanced diagnostic and therapeutic options
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Peritoneal Cancer Market Research Report
By Type
Surgery, Chemotherapy (Anticancer Drugs), Radiotherapy (High-Energy Rays)
By Application
Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics
By Companies
AstraZeneca, GlaxoSmithKline, Oxford BioMedica, Millennium Pharmaceuticals, Novartis, Bayer, Incyte, EntreMed, Oncolytics Biotech, Synta Pharmaceuticals, Oasmia Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
196
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Peritoneal Cancer Market Report Segments:
The global Peritoneal Cancer market is segmented on the basis of:
Types
Surgery, Chemotherapy (Anticancer Drugs), Radiotherapy (High-Energy Rays)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- GlaxoSmithKline
- Oxford BioMedica
- Millennium Pharmaceuticals
- Novartis
- Bayer
- Incyte
- EntreMed
- Oncolytics Biotech
- Synta Pharmaceuticals
- Oasmia Pharmaceutical
Highlights of The Peritoneal Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Surgery
- Chemotherapy (Anticancer Drugs)
- Radiotherapy (High-Energy Rays)
- By Application:
- Cancer Research Centers
- Cancer Hospital
- Surgical Centers
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peritoneal Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peritoneal cancer is a type of cancer that develops in the peritoneum, the membrane that lines the abdominal cavity and surrounds many internal organs. The peritoneum can become inflamed (swollen) due to a number of factors, including infection, injury, or disease. If this swelling becomes large enough, it can press on vital organs within the abdomen and cause them to malfunction. Peritonitis (inflammation of the peritoneum) is one common complication of peritoneal cancer.
Some of the key players operating in the peritoneal cancer market are AstraZeneca, GlaxoSmithKline, Oxford BioMedica, Millennium Pharmaceuticals, Novartis, Bayer, Incyte, EntreMed, Oncolytics Biotech, Synta Pharmaceuticals, Oasmia Pharmaceutical.
The peritoneal cancer market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Peritoneal Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Peritoneal Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Peritoneal Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Peritoneal Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Peritoneal Cancer Market Size & Forecast, 2020-2028
4.5.1 Peritoneal Cancer Market Size and Y-o-Y Growth
4.5.2 Peritoneal Cancer Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Surgery
5.2.2 Chemotherapy (Anticancer Drugs)
5.2.3 Radiotherapy (High-Energy Rays)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer Research Centers
6.2.2 Cancer Hospital
6.2.3 Surgical Centers
6.2.4 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Peritoneal Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Peritoneal Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Surgery
9.6.2 Chemotherapy (Anticancer Drugs)
9.6.3 Radiotherapy (High-Energy Rays)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer Research Centers
9.10.2 Cancer Hospital
9.10.3 Surgical Centers
9.10.4 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Surgery
10.6.2 Chemotherapy (Anticancer Drugs)
10.6.3 Radiotherapy (High-Energy Rays)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer Research Centers
10.10.2 Cancer Hospital
10.10.3 Surgical Centers
10.10.4 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Surgery
11.6.2 Chemotherapy (Anticancer Drugs)
11.6.3 Radiotherapy (High-Energy Rays)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer Research Centers
11.10.2 Cancer Hospital
11.10.3 Surgical Centers
11.10.4 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Surgery
12.6.2 Chemotherapy (Anticancer Drugs)
12.6.3 Radiotherapy (High-Energy Rays)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer Research Centers
12.10.2 Cancer Hospital
12.10.3 Surgical Centers
12.10.4 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Surgery
13.6.2 Chemotherapy (Anticancer Drugs)
13.6.3 Radiotherapy (High-Energy Rays)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer Research Centers
13.10.2 Cancer Hospital
13.10.3 Surgical Centers
13.10.4 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Peritoneal Cancer Market: Competitive Dashboard
14.2 Global Peritoneal Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 GlaxoSmithKline
14.3.3 Oxford BioMedica
14.3.4 Millennium Pharmaceuticals
14.3.5 Novartis
14.3.6 Bayer
14.3.7 Incyte
14.3.8 EntreMed
14.3.9 Oncolytics Biotech
14.3.10 Synta Pharmaceuticals
14.3.11 Oasmia Pharmaceutical
